Jounce Therapeutics, Inc. (NASDAQ:JNCE) has received an average broker rating score of 1.00 (Strong Buy) from the four brokers that cover the company, Zacks Investment Research reports. Four investment analysts have rated the stock with a strong buy rating.

Analysts have set a 12 month consensus price target of $30.00 for the company and are anticipating that the company will post ($0.25) earnings per share for the current quarter, according to Zacks. Zacks has also given Jounce Therapeutics an industry rank of 101 out of 265 based on the ratings given to its competitors.

Several equities research analysts recently weighed in on the company. Zacks Investment Research cut Jounce Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, May 12th. Cowen and Company reaffirmed a “buy” rating on shares of Jounce Therapeutics in a research note on Friday, June 9th.

Shares of Jounce Therapeutics (NASDAQ JNCE) traded up 2.37% on Wednesday, reaching $15.96. 62,363 shares of the company’s stock were exchanged. Jounce Therapeutics has a 52-week low of $11.05 and a 52-week high of $29.29. The stock has a market cap of $513.18 million and a P/E ratio of 591.11. The company’s 50 day moving average price is $13.29 and its 200-day moving average price is $19.32.

Jounce Therapeutics (NASDAQ:JNCE) last issued its quarterly earnings results on Wednesday, August 9th. The company reported ($0.11) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.15) by $0.04. The firm had revenue of $20.29 million during the quarter, compared to analysts’ expectations of $19.94 million. During the same period in the previous year, the company earned ($7.23) earnings per share. Equities analysts forecast that Jounce Therapeutics will post ($0.62) EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Jounce Therapeutics, Inc. (JNCE) Given Average Rating of “Strong Buy” by Analysts” was originally published by Watch List News and is the property of of Watch List News. If you are viewing this piece on another publication, it was stolen and republished in violation of international copyright and trademark law. The original version of this piece can be viewed at https://www.watchlistnews.com/jounce-therapeutics-inc-jnce-given-average-rating-of-strong-buy-by-analysts/1532008.html.

Several large investors have recently added to or reduced their stakes in the company. Paloma Partners Management Co bought a new stake in Jounce Therapeutics during the first quarter worth approximately $212,000. TIAA CREF Investment Management LLC bought a new stake in Jounce Therapeutics during the first quarter worth approximately $229,000. Teachers Advisors LLC boosted its stake in Jounce Therapeutics by 26.4% in the second quarter. Teachers Advisors LLC now owns 11,231 shares of the company’s stock worth $158,000 after buying an additional 2,347 shares in the last quarter. ARK Investment Management LLC boosted its stake in Jounce Therapeutics by 558.9% in the second quarter. ARK Investment Management LLC now owns 11,932 shares of the company’s stock worth $167,000 after buying an additional 10,121 shares in the last quarter. Finally, Nationwide Fund Advisors boosted its stake in Jounce Therapeutics by 203.3% in the second quarter. Nationwide Fund Advisors now owns 11,946 shares of the company’s stock worth $168,000 after buying an additional 8,007 shares in the last quarter. 43.50% of the stock is currently owned by hedge funds and other institutional investors.

Jounce Therapeutics Company Profile

Jounce Therapeutics, Inc is a clinical-stage immunotherapy company. The Company is engaged in developing therapies that enable the immune system to attack tumors. Through the use of its Translational Science Platform, the Company first focuses on specific cell types within tumors to prioritize targets, and then identify related biomarkers designed to match the right therapy to the right patient.

Get a free copy of the Zacks research report on Jounce Therapeutics (JNCE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Jounce Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jounce Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.